

Clinical trials of Efamol marine

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
Efamol marine vs placebo			
Veale , 1994 n=19/19 follow-up: 9 months	Efamol marine capsules, 12/d (0.4g/d EPA + DHA plus 0.5g/d gamma-linoleic acid (notomega-3))TP versus placebo (capsules containing liquid paraffin and vitamin E, 12/d, appeared identical)	people with chronic stable plaque psoriasis and inflammatory arthritis	Parallel groups double blind UK

More details and results :

- omega-3 fatty acids for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q121>
- omega-3 fatty acids for cardiovascular prevention in pateints at low risk at <http://www.trialresultscenter.org/go-Q124>

References

Veale, 1994:

Veale DJ, Torley HI, Richards IM, O'Dowd A, Fitzsimons C, Belch JJ, Sturrock RD A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. Br J Rheumatol 1994;33:954-8 [[7921757](#)]